Il-6-Mediated Management as an Evolving, Evidence-Supported Treatment Paradigm for RA: Optimizing the Benefit-to-Risk Equation Across the Morbidity and Therapeutic Spectrum for Rheumatoid Arthritis — A Year 2015, Advanced Practice Analysis and Summary Statement - Mark C. Genovese, MD – Program Chair Professor of Medicine Co-Chief, Division of Immunology and Rheumatology Stanford University